Nonresponder patients with breast and cervical cancer treated with abiraterone or everolimus had more alterations in TP53. None of the four patients who experienced an objective response or disease stabilization that lasted longer than 6 months and for whom a complete molecular profile was available had a mutation in the TP53 gene compared with 10 (31%) of 32 nonresponders with a complete molecular profile (P = .47; Data Supplement). This evidence concerns the gene TP53 and cervical carcinoma.